adg126,tpst-1120,sorafenib,bevacizumab,tocilizumab,atezolizumab,ro7247669,tiragolumab
adagene,roche,jw pharma,tempest
['morpheus-liver', 'imbrave-150', '$rhhby']
r finn tackles underperforming morpheus-liver control arm vs imbrave-150: "hybrid" control still positive $rhhby #asco23 
Once had a blue tick. Journalist at Evaluate Vantage. Interested in: oncology, immunology. Not interested in: what stock you bought today.